相似文献
1
Invasive aspergillosis caused by Aspergillus ustus: case report and review.
J Clin Microbiol. 1999 May;37(5):1606-9. doi: 10.1128/JCM.37.5.1606-1609.1999.
2
Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation.
J Clin Microbiol. 1998 Dec;36(12):3713-7. doi: 10.1128/JCM.36.12.3713-3717.1998.
3
Efficacy of Antifungal Monotherapies and Combinations against Aspergillus calidoustus.
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01137-18. Print 2018 Dec.
4
Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient.
J Am Acad Dermatol. 1994 Aug;31(2 Pt 2):344-7. doi: 10.1016/s0190-9622(94)70169-5.
5
Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.
Diagn Microbiol Infect Dis. 2008 Dec;62(4):443-6. doi: 10.1016/j.diagmicrobio.2008.08.003. Epub 2008 Oct 7.
6
Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection.
J Clin Microbiol. 2004 Oct;42(10):4805-8. doi: 10.1128/JCM.42.10.4805-4808.2004.
7
Aspergillus ustus infections among transplant recipients.
Emerg Infect Dis. 2006 Mar;12(3):403-8. doi: 10.3201/eid1203.050670.
8
Aspergillus infections: problems in diagnosis and treatment.
Infect Agents Dis. 1996 Jan;5(1):47-54.
9
Cutaneous infection caused by Aspergillus ustus, an emerging opportunistic fungus in immunosuppressed patients.
J Clin Microbiol. 2001 Mar;39(3):1134-6. doi: 10.1128/JCM.39.3.1134-1136.2001.
10
Cutaneous Aspergillus ustus in a lung transplant recipient: emergence of a new opportunistic fungal pathogen.
J Heart Lung Transplant. 2008 Jan;27(1):131-4. doi: 10.1016/j.healun.2007.09.020.
引用本文的文献
1
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0003423. doi: 10.1128/cmr.00034-23. Epub 2024 May 1.
2
A Collaborative Tale of Diagnosing and Treating Chronic Pulmonary Aspergillosis, from the Perspectives of Clinical Microbiologists, Surgical Pathologists, and Infectious Disease Clinicians.
J Fungi (Basel). 2020 Jul 11;6(3):106. doi: 10.3390/jof6030106.
3
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.
Mycopathologia. 2020 Apr;185(2):399-403. doi: 10.1007/s11046-019-00423-x. Epub 2020 Jan 10.
4
Aspergillus pseudodeflectus: a new human pathogen in liver transplant patients.
BMC Infect Dis. 2018 Dec 12;18(1):648. doi: 10.1186/s12879-018-3527-5.
5
Efficacy of Antifungal Monotherapies and Combinations against Aspergillus calidoustus.
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01137-18. Print 2018 Dec.
6
Antifungal susceptibility profile of cryptic species of Aspergillus.
Mycopathologia. 2014 Dec;178(5-6):427-33. doi: 10.1007/s11046-014-9775-z. Epub 2014 Jun 28.
7
Aerial prevalence of Aspergillus calidoustus isolates in and around a tertiary care hospital in Kuwait and assessment of their pathogenicity.
J Clin Microbiol. 2014 Sep;52(9):3402-5. doi: 10.1128/JCM.01181-14. Epub 2014 Jun 11.
8
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
9
In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.
Antimicrob Agents Chemother. 2012 Aug;56(8):4500-3. doi: 10.1128/AAC.00045-12. Epub 2012 May 21.
10
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.
Infect Drug Resist. 2012;5:9-16. doi: 10.2147/IDR.S22587. Epub 2012 Jan 11.
本文引用的文献
1
2
Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation.
J Clin Microbiol. 1998 Dec;36(12):3713-7. doi: 10.1128/JCM.36.12.3713-3717.1998.
3
Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation.
Med Mycol. 1998 Jun;36(3):165-8.
4
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
J Antimicrob Chemother. 1998 Jul;42(1):91-4. doi: 10.1093/jac/42.1.91.
5
Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease.
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1694-6. doi: 10.1164/ajrccm.157.5.9709068.
6
Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.
Clin Infect Dis. 1998 May;26(5):1092-7. doi: 10.1086/520297.
7
Primary cutaneous Aspergillus ustus infection: second reported case.
J Am Acad Dermatol. 1998 May;38(5 Pt 2):797-8. doi: 10.1016/s0190-9622(98)70460-8.
8
Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole.
Clin Infect Dis. 1998 Apr;26(4):996-7. doi: 10.1086/517646.
9
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Antimicrob Agents Chemother. 1998 Apr;42(4):873-8. doi: 10.1128/AAC.42.4.873.
10
Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients.
J Infect. 1997 Jul;35(1):7-15. doi: 10.1016/s0163-4453(97)90833-1.
Zotero 插件